Patents by Inventor Andrew Hamblin

Andrew Hamblin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIGEN BINDING PROTEINS
    Publication number: 20230295295
    Abstract: This application discloses antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Application
    Filed: January 19, 2023
    Publication date: September 21, 2023
    Inventors: Paul Andrew HAMBLIN, Alan Peter Lewis, Thomas Matthew Webb
  • ANTIGEN BINDING PROTEINS
    Publication number: 20230242642
    Abstract: Antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Application
    Filed: January 11, 2023
    Publication date: August 3, 2023
    Inventors: Paul Andrew HAMBLIN, Alan Peter Lewis, Thomas Matthew Webb
  • ANTIGEN BINDING PROTEINS
    Publication number: 20230137032
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Application
    Filed: July 12, 2022
    Publication date: May 4, 2023
    Inventors: Paul ALGATE, Stephanie Jane CLEGG, Jennifer L. CRAIGEN, Paul Andrew HAMBLIN, Alan Peter LEWIS, Patrick MAYES, Radha Shah PARMAR, Trevor Anthony Kenneth WATTAM
  • Antigen binding proteins
    Patent number: 11419945
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: August 23, 2022
    Assignee: GLAXO GROUP LIMITED
    Inventors: Paul Algate, Stephanie Jane Clegg, Jennifer L. Craigen, Paul Andrew Hamblin, Alan Peter Lewis, Patrick Mayes, Radha Shah Parmar, Trevor Anthony Kenneth Wattam
  • Method of treatment with humanized anti-IL-18 antibodies
    Patent number: 10703814
    Abstract: The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: July 7, 2020
    Assignee: Glaxo Group Limited
    Inventors: Jonathan Henry Ellis, Volker Germaschewski, Paul Andrew Hamblin
  • ANTIGEN BINDING PROTEINS
    Publication number: 20200197529
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Application
    Filed: March 11, 2020
    Publication date: June 25, 2020
    Inventors: Paul Algate, Stephanie Jane Clegg, Jennifer L. Craigen, Paul Andrew Hamblin, Alan Peter Lewis, Patrick Mayes, Radha Shah Parmar, Trevor Anthony Kenneth Wattam
  • ANTIGEN BINDING PROTEINS
    Publication number: 20190382482
    Abstract: This application discloses antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Application
    Filed: May 30, 2019
    Publication date: December 19, 2019
    Inventors: Paul Andrew HAMBLIN, Alan Peter Lewis, Thomas Matthew Webb
  • ANTIGEN BINDING PROTEINS
    Publication number: 20190276535
    Abstract: Antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Application
    Filed: March 19, 2019
    Publication date: September 12, 2019
    Inventors: Paul Andrew HAMBLIN, Alan Peter Lewis, Thomas Matthew WEBB
  • Antigen binding proteins
    Patent number: 10344088
    Abstract: This application discloses antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 9, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Paul Andrew Hamblin, Alan Peter Lewis, Thomas Matthew Webb
  • Anti-LAG-3 binding proteins
    Patent number: 10280221
    Abstract: Antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 7, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Paul Andrew Hamblin, Alan Peter Lewis, Thomas Matthew Webb
  • HUMANIZED ANTI-IL-18 ANTIBODIES
    Publication number: 20190031753
    Abstract: The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.
    Type: Application
    Filed: October 16, 2018
    Publication date: January 31, 2019
    Inventors: Jonathan Henry ELLIS, Volker Germaschewski, Paul Andrew Hamblin
  • ANTIGEN BINDING PROTEINS
    Publication number: 20180147293
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Application
    Filed: December 1, 2017
    Publication date: May 31, 2018
    Inventors: PAUL ALGATE, STEPHANIE JANE CLEGG, JENNIFER L. CRAIGEN, PAUL ANDREW HAMBLIN, ALAN PETER LEWIS, PATRICK MAYES, RADHA SHAH PARMAR, TREVOR ANTHONY KENNETH WATTAM
  • IMMUNOGLOBULINS
    Publication number: 20170029497
    Abstract: The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.
    Type: Application
    Filed: October 14, 2016
    Publication date: February 2, 2017
    Inventors: Jonathan Henry ELLIS, Volker GERMASCHEWSKI, Paul Andrew HAMBLIN
  • Humanized anti-IL-18 antibodies
    Patent number: 9499617
    Abstract: The present invention discloses humanized anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: November 22, 2016
    Assignee: Glaxo Group Limited
    Inventors: Jonathan Henry Ellis, Volker Germaschewski, Paul Andrew Hamblin
  • ANTIGEN-BINDING CONSTRUCTS
    Publication number: 20160207993
    Abstract: The invention relates to antigen-binding constructs comprising a protein scaffold which are linked to one or more epitope-binding domains wherein the antigen-binding construct has at least two antigen binding sites at least one of which is from an epitope binding domain and at least one of which is from a paired VH/VL domain, methods of making such constructs and uses thereof.
    Type: Application
    Filed: June 15, 2015
    Publication date: July 21, 2016
    Inventors: Claire ASHMAN, Thil Batuwangala, Michael Neil Burden, Stephanie Jane Clegg, Rudolf Maria De Wildt, Jonathan Henry Ellis, Paul Andrew Hamblin, Farhana Hussain, Laurent Jespers, Alan Lewis, Martin Anibal Orecchia, Radha Shah, Michael Steward
  • Antigen-binding proteins
    Patent number: 9394374
    Abstract: The invention relates to linkers suitable for use in antigen-binding proteins, certain antigen binding proteins and methods of making such proteins and uses thereof.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: July 19, 2016
    Assignee: Glaxo Group Limited
    Inventors: Paul Andrew Hamblin, Alan Peter Lewis, Martin Anibal Orecchia, Radha Shah Parmar
  • ANTIGEN BINDING PROTEINS
    Publication number: 20160193358
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Application
    Filed: December 18, 2015
    Publication date: July 7, 2016
    Inventors: Paul Algate, Stephanie Jane Clegg, Jennifer L. Craigen, Paul Andrew Hamblin, Alan Peter Lewis, Patrick Mayes, Radha Shah Parmar, Trevor Anthony Kenneth Wattam
  • B cell maturation antigen (BCMA) binding proteins
    Patent number: 9273141
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: March 1, 2016
    Assignee: Glaxo Group Limited
    Inventors: Paul Algate, Stephanie Jane Clegg, Jennifer L. Craigen, Paul Andrew Hamblin, Alan Peter Lewis, Patrick Mayes, Radha Shah Parmar, Trevor Anthony Kenneth Wattam
  • ANTI-LAG-3 BINDING PROTEINS
    Publication number: 20160017037
    Abstract: Antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 21, 2016
    Inventors: Paul Andrew HAMBLIN, Alan Peter LEWIS, Thomas Matthew WEBB
  • NOGO-A Neutralizing Immunoglobulins for the Treatment of Neurological Diseases
    Publication number: 20140147435
    Abstract: The present invention relates to antibodies to NOGO, pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders.
    Type: Application
    Filed: May 7, 2013
    Publication date: May 29, 2014
    Inventors: Jonathan Henry ELLIS, Paul Andrew Hamblin, Alan Peter Lewis, Paul Alexander Wilson